A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Tyligand Pharmaceuticals (Suzhou) Limited
DEKA Biosciences
Northwestern University
Gilead Sciences
National Institutes of Health Clinical Center (CC)